Dianthus Therapeutics (DNTH)

• Market cap: $6.16B
• 1 day: 8.21%
• 5 days: 6.14%
• 1 month: 15.55%
• 3 months: 28.29%
• 6 months: 110.98%
• Year to date: 183.87%
• 1 year: 441.54%
• 5 years: -1.12%
• 10 years: -51.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Employees: 92